140P - Brigatinib experience on the ALK project by Gomes F et al.
Results:Of 335 ALKþNSCLC patients with follow-up between Jan 2015Sep 2017, 32
(9.5%) patients were treated with IO therapy. Median age was 62.5 years, with 78.1% of
patients diagnosed at stage IV, and 24 patients receiving nivolumab. Of the 32 IO
treated patients, 15.6% received IO therapy before first ALK TKI, and 59.4%were
treated with IO therapy after2 ALK TKIs. Median (95% CI) time to discontinuation
of IO therapy was 1.88 months (0.95 2.80), rwPFS was 2.17 months (1.18 2.93),
and OS was 6.71months (2.80NE).
Conclusions:We identified ALKþNSCLC patients who received IO therapy; most of
whomwere treated post ALK TKI. Time to discontinuation of IO therapy was short,
and real-world effectiveness (rwPFS andOS) was limited. These results point to IO
therapy’s relative futility in ALKþNSCLC patients. Compared to IO therapy, several
approved ALK inhibitors have shown better effectiveness in both first and later lines of
therapy. However, the optimal sequencing of ALK inhibitors with other therapies,
including chemotherapy and IO therapy, remains unclear.
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Background: The ALK Project established a network across the UKwith the aim to ana-
lyse treatment patterns/outcomes and promote collaborations and research. The treat-
ment pathway for ALKþ patients has been revolutionised in recent years.
Methods: Amulticentre retrospective analysis across 32 NHS hospitals/trusts identified
196 ALKþ non-small cell lung cancer (NSCLC) patients who were offered treatment by
Dec-2018. Patients who received brigatinib during their treatment pathway were
selected. The primary aims were 2-years overall survival (OS) andmedian OS from start
of brigatinib. The secondary aims were objective response rate (ORR), incidence of
grade 3-4 toxicity and 5-years/median OS from diagnosis of advanced NSCLC.
Results:A total of 50 patients were included with 48% beingmales, 70% never smoked
tobacco and the median age at diagnosis was 50 years. 66% of patients developed brain
metastasis at some point during their care and 52% had brain metastasis at the start of
brigatinib. Brigatinib was used as the first, second or subsequent ALK inhibitor in 18%,
50% and 32% of cases, respectively. 82% of patients were exposed to other ALK inhibi-
tors during their treatment pathway and 46% received chemotherapy prior to the start
of any ALK inhibitor. On amedian follow-up (since start of brigatinib) of 10 months,
patients stayed on brigatinib for a median of 9 months (95%CI, 3.1-14.9), reaching 14
months (95%CI 11.0-19.9) if no brain metastasis (p¼ 0.15). The overall ORR was 64%
and the incidence of grade 3-4 toxicity was 16%.Median OS from start of brigatinib
was not reached and the 2-years OS according to brain metastasis was 61% or 83%, in
favour of those without brain metastasis (p¼ 0.037). The median OS from diagnosis of
advanced NSCLC was not reached and the 5-years OS was 55%.
Conclusions: Brigatinib is well tolerated and an effective treatment even in heavily pre-
treated patients or in those with brain metastasis. A nationwide collaboration is possi-
ble and revealed the remarkable survival improvements for ALKþ patients with the
development of newer generations of ALK inhibitors.
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Background: CNS is a common site of metastases in patients with ALK-positive
NSCLC. CNSmetastases are associated with a number of deleterious effects, such as
reduction in quality of life. However, the relationship between brain metastases and
prognosis remains unclear. We aimed to evaluate the effect of CNSmetastases on over-
all survival (OS) in amulticenter cohort of Spanish ALK-positive NSCLC patients diag-
nosed between 2008 and 2017.
Methods:We included patients with stage IV at diagnoses, followed up to April 2018;
OS (months [m]) was estimated with the Kaplan-Meier method. Survival curves were
compared between groups of patients using the log-rank test. Hazard risk (HR) to
death was estimated with multivariable Coxmodel.
Results:Out of 163 patients in the cohort, a total of 116 were evaluated, with a median
of follow-up of 29.2m and 59 deaths reported. Characteristics at diagnosis were a
median age of 58 years, 50% female, 58.6% never-smokers, 54.3% with comorbidities,
PS by ECOG 0-1 93.1%. CNSmetastases (median number of lesions 6) were present in
43.1% of patients and 34% of patients with CNSmetastases were treated with local
therapy (11.8 % local radiotherapy and 76.5% holocraneal radiotherapy). ALK inhibi-
tors as first line and second line treatment were administered to 45.5% and 78.6% of
patients, respectively. Themedian OS was 39months; OS in patients with CNSmeta-
stases at diagnosis was 34.4 m and 39.0 m in those without CNSmetastases at diagnosis
(p=.9). In patients without CNSmetastases at baseline (n=60), 22 developed CNS, with
amedian OS greater than in those without CNSmetastases during follow-up, although
the difference is not significant (45.5 m vs 33.3 m; p=.9). There were 81 patients who
presented with metastases in more than one organ and 33 patients with metastases in a
single organ. The risk of death increased as the number of metastatic organs at diagno-
ses increased (HR=1.26, p=.0305), with worse OS in those presenting with liver meta-
stases at diagnoses (21.1%, OS: 20 m), compared to those without tumor involvement
(OS: 45.4 m; p =.008).
Conclusions:OSwas similar for ALK-positive NSCLC patients with and without CNS
metastases at diagnoses. OS was worse as the number of metastatic organs at diagnosis
increased, with liver metastases being associated with the highest risk of mortality.
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Background: Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs)
have been demonstrated to be effective in ALK-rearranged, advanced lung adenocarci-
noma patients. However, data from a real-world setting is very limited. The aim of the
study was to: a) determine long-term survival in these patients and investigate factors
associated with their prognosis; and b) analyze the clinical outcomes of patients who
were sequentially treated with next-generation ALK-TKIs.
Methods: ALK-rearranged, advanced lung adenocarcinoma patients who were treated
with crizotinib were included between January 2013 and December 2016. Progression-
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